Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD).

Biosimilars are biological drugs which are similar to the authorized biologics (“reference productâ€) but not identical (1). The European legislation has offered since 2006 a legal framework for biosimilars. The concept and methodology of the comparative investigations are further treated in the guidelines of the European Medicines Agency (EMA) [.]